A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies

Brain

Volumn 139, Issue 5, 2016, Pages 1587-1604

  Lathuilière, Aurelien ^a   Laversenne, Vanessa ^a   Astolfo, Alberto ^b   Kopetzki, Erhard ^c   Jacobsen, Helmut ^d   Stampanoni, Marco ^b   Bohrmann, Bernd ^d   Schneider, Bernard L ^a   Aebischer, Patrick ^a  

^a EPFL   (Switzerland)

^b PAUL SCHERRER INSTITUTE   (Switzerland)

^c DTA Neuroscience   (Switzerland)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Alzheimer's disease; antibody; cellular implant; encapsulation; immunization

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; PRESENILIN 2; RECOMBINANT AMYLOID BETA PROTEIN ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); DRUG IMPLANT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CELL ENCAPSULATION; CELLULAR IMPLANT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GENETIC ENGINEERING; GRAFT RECIPIENT; IMMUNOCOMPETENCE; IMPLANT; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; LONG TERM SURVIVAL; MACROMOLECULE; MICROENCAPSULATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PLASMA; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL CULTURE; DRUG IMPLANT; IMMUNOLOGY; METABOLISM; NEUROPROTECTION; PROCEDURES; SKIN ABSORPTION; TAUOPATHIES; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELLS, CULTURED; DRUG IMPLANTS; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC; NEUROPROTECTION; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; RECOMBINANT PROTEINS; SUBCUTANEOUS ABSORPTION; TAUOPATHIES;

EID: 84966549018     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww036     Document Type: Article

References (63)

1. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012; 32: 9677-89.
2. Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, Heyd B, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2: 696-9.
3. Alliot F, Marty MC, Cambier D, Pessac B. A spontaneously immortalized mouse microglial cell line expressing CD4. Brain Res Dev Brain Res 1996; 95: 140-3.
4. Astolfo A, Arfelli F, Schultke E, James S, Mancini L, Menk RH. A detailed study of gold-nanoparticle loaded cells using X-ray based techniques for cell-tracking applications with single-cell sensitivity. Nanoscale 2013; 5: 3337-45.
5. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002; 22: 7873-8.
6. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, et al. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 2012; 32: 13454-69.
7. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003; 100: 2023-8.
8. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-19.
9. Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med 2014; 211: 233-44.
10. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 2010; 120: 13-20.
11. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cellmediated removal of human amyloid-beta. J Alzheimers Dis 2012; 28: 49-69.
12. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9096-101.
13. Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE 2011; 6: e18296
14. Charrier S, Stockholm D, Seye K, Opolon P, Taveau M, Gross DA, et al. A lentiviral vector encoding the human Wiskott-Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice. Gene Ther 2005; 12: 597-606.
15. Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Brain 2014; 137: 2834-46.
16. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001; 22: 721-7.
17. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-5.
18. Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, et al. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron 2012; 76: 908-20.
19. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370: 311-21.
20. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996; 62: 155-69.
21. Ehrbar M, Rizzi SC, Schoenmakers RG, Miguel BS, Hubbell JA, Weber FE, et al. Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions. Biomacromolecules 2007; 8: 3000-7.
22. Fuller JP, Stavenhagen JB, Teeling JL. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front Neurosci 2014; 8: 235
23. Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005; 39: 364-75.
24. Goate A, Hardy J. Twenty years of Alzheimer's disease-causing mutations. J Neurochem 2012; 120: 3-8.
25. Gros-Louis F, Soucy G, Lariviere R, Julien JP. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J Neurochem 2010; 113: 1188-99.
26. Grueninger F, Bohrmann B, Czech C, Ballard TM, Frey JR, Weidensteiner C, et al. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 2010; 37: 294-306.
27. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
28. Lathuiliere A, Bohrmann B, Kopetzki E, Schweitzer C, Jacobsen H, Moniatte M, et al. Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation. Biomaterials 2014a; 35: 792-802.
29. Lathuiliere A, Cosson S, Lutolf MP, Schneider BL, Aebischer P. A high-capacity cell macroencapsulation system supporting the longterm survival of genetically engineered allogeneic cells. Biomaterials 2014b; 35: 779-91.
30. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, et al. Anti-Abeta42-and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 2006; 116: 193-201.
31. Marroquin Belaunzaran O, Cordero MI, Setola V, Bianchi S, Galli C, Bouche N, et al. Chronic delivery of antibody fragments using immunoisolated cell implants as a passive vaccination tool. PLoS ONE 2011; 6: e18268
32. McDonald SA, Marone F, Hintermuller C, Mikuljan G, David C, Pfeiffer F, et al. Advanced phase-contrast imaging using a grating interferometer. J Synchrotron Radiat 2009; 16: 562-72.
33. Negroni E, Riederer I, Chaouch S, Belicchi M, Razini P, Di Santo J, et al. In vivo myogenic potential of human CD133 + muscle-derived stem cells: a quantitative study. Mol Ther 2009; 17: 1771-8.
34. Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014; 81: 49-60.
35. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26: 10129-40
36. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-32.
37. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012; 69: 198-207.
38. Pinzer BR, Cacquevel M, Modregger P, McDonald SA, Bensadoun JC, Thuering T, et al. Imaging brain amyloid deposition using grating-based differential phase contrast tomography. Neuroimage 2012; 61: 1336-46.
39. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005; 25: 629-36.
40. Rauchenberger R, Borges E, Thomassen-Wolf E, Rom E, Adar R, Yaniv Y, et al. Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J Biol Chem 2003; 278: 38194-205.
41. Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2013; 10: 217-28.
42. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med 2014; 370: 322-33.
43. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20: vi3-9.
44. Serrano-Pozo A, William CM, Ferrer I, Uro-Coste E, Delisle MB, Maurage CA, et al. Beneficial effect of human anti-amyloid-active immunization on neurite morphology and tau pathology. Brain 2010; 133: 1312-27.
45. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48: 1267-81.
46. Skoldunger A, Wimo A, Johnell K. Net costs of dementia in Sweden-an incidence based 10 year simulation study. Int J Geriatr Psychiatry 2012; 27: 1112-17.
47. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012; 11: 241-9.
48. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
49. Tabrizi M, Bornstein GG, Suria H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 2010; 12: 33-43.
50. Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, Tajima N, et al. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol Dis 2005; 20: 541-9.
51. Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci 2011; 31: 4124-36.
52. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-58.
53. Wang YJ, Gao CY, Yang M, Liu XH, Sun Y, Pollard A, et al. Intramuscular delivery of a single chain antibody gene prevents brain Abeta deposition and cognitive impairment in a mouse model of Alzheimer's disease. Brain Behav Immun 2010; 24: 1281-93.
54. Webster SD, Galvan MD, Ferran E, Garzon-Rodriguez W, Glabe CG, Tenner AJ. Antibody-mediated phagocytosis of the amyloid betapeptide in microglia is differentially modulated by C1q. J Immunol 2001; 166: 7496-503.
55. Weitkamp T, Diaz A, David C, Pfeiffer F, Stampanoni M, Cloetens P, et al. X-ray phase imaging with a grating interferometer. Opt Express 2005; 13: 6296-304.
56. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, et al. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 2006a; 26: 5340-6.
57. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 2009; 29: 7957-65.
58. Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 2006b; 1: 1591-5.
59. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004a; 24: 6144-51.
60. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004b; 1: 24.
61. Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977; 270: 725-7.
62. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in agerelated macular degeneration. Proc Natl Acad Sci USA 2011; 108: 6241-5.
63. Zufferey R. Production of lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 107-21.